Lithium and valproate levels do not correlate with ketamine's antidepressant efficacy in treatment-resistant bipolar depression

Neural Plasticity

Volumn 2015, Issue , 2015, Pages

  Xu, Annie J ^a   Niciu, Mark J ^b   Lundin, Nancy B ^b   Luckenbaugh, David A ^b   Ionescu, Dawn F ^c   Richards, Erica M ^b   Vande Voort, Jennifer L ^d   Ballard, Elizabeth D ^b   Brutsche, Nancy E ^b   Machado Vieira, Rodrigo ^b   Zarate, Carlos A ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; LITHIUM; VALPROIC ACID; ANTIDEPRESSANT AGENT;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSOCIATIVE DISORDER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; FEMALE; HUMAN; LITHIUM BLOOD LEVEL; MALE; MENTAL DISEASE; MENTAL PATIENT; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; VALPROATE BLOOD LEVEL; BIPOLAR DISORDER; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CROSSOVER PROCEDURE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE BLIND PROCEDURE; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KETAMINE; LITHIUM; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84935029240     PISSN: 20905904     EISSN: 16875443     Source Type: Journal    
DOI: 10.1155/2015/858251     Document Type: Article

References (40)

1. R. J. Baldessarini, E. Vieta, J. R. Calabrese, M. Tohen, and C. L. Bowden, "Bipolar depression: overview and commentary, " Harvard Review of Psychiatry, vol. 18, no. 3, pp. 143-157, 2010.
2. S. Tirupati and L.-E. Chua, "Obesity and metabolic syndrome in a psychiatric rehabilitation service, " Australian and New Zealand Journal of Psychiatry, vol. 41, no. 7, pp. 606-610, 2007.
3. L. Maayan and C. U. Correll, "Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents, " Journal of Child and Adolescent Psychopharmacology, vol. 21, no. 6, pp. 517-535, 2011.
4. N. Diazgranados, L. Ibrahim, N. E. Brutsche et al., "A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression, " Archives of General Psychiatry, vol. 67, no. 8, pp. 793-802, 2010.
5. C. A. Zarate Jr., N. E. Brutsche, L. Ibrahim et al., "Replication of ketamines antidepressant efficacy in bipolar depression: a randomized controlled add-on trial, " Biological Psychiatry, vol. 71, no. 11, pp. 939-946, 2012.
6. J. K. Rybakowski, A. Permoda-Osip, M. Skibinska, R. Adamski, and A. Bartkowska-Sniatkowska, "Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?" Human Psychopharmacology, vol. 28, no. 1, pp. 87-90, 2013.
7. M. J. Niciu, D. A. Luckenbaugh, D. F. Ionescu, D. C. Mathews, E. M. Richards, and C. A. Zarate Jr., "Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression, " Biological Psychiatry, vol. 74, no. 10, pp. e23-e24, 2013.
8. E.-M. Hur and F.-Q. Zhou, "GSK3 signalling in neural development, " Nature Reviews Neuroscience, vol. 11, no. 8, pp. 539-551, 2010.
9. R. S. Jope, "Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes, " Trends in Pharmacological Sciences, vol. 24, no. 9, pp. 441-443, 2003.
10. P. S. Klein and D. A. Melton, "A molecular mechanism for the effect of lithium on development, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8455-8459, 1996.
11. V. Stambolic, L. Ruel, and J. R. Woodgett, "Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells, " Current Biology, vol. 6, no. 12, pp. 1664-1668, 1996.
12. W. J. Ryves and A. J. Harwood, "Lithium inhibits glycogen synthase kinase-3 by competition for magnesium, " Biochemical and Biophysical Research Communications, vol. 280, no. 3, pp. 720-725, 2001.
13. E. Beurel, L. Song, and R. S. Jope, "Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice, " Molecular Psychiatry, vol. 16, no. 11, pp. 1068-1070, 2011.
14. M. Ghasemi, M. Raza, and A. R. Dehpour, "NMDA receptor antagonists augment antidepressant-like effects of lithiumin the mouse forced swimming test, " Journal of Psychopharmacology, vol. 24, no. 4, pp. 585-594, 2010.
15. R.-J. Liu, M. Fuchikami, J. M. Dwyer, A. E. Lepack, R. S. Duman, and G. K. Aghajanian, "GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine, " Neuropsychopharmacology, vol. 38, no. 11, pp. 2268-2277, 2013.
16. M. Atmaca, "Valproate and neuroprotective effects for bipolar disorder, " International Review of Psychiatry, vol. 21, no. 4, pp. 410-413, 2009.
17. H. A. Sackeim, "The definition and meaning of treatmentresistant depression, " Journal of Clinical Psychiatry, vol. 62, supplement 16, pp. 10-17, 2001.
18. M. J. Niciu, D. A. Luckenbaugh, D. F. Ionescu et al., "Clinical predictors of ketamine response in treatment-resistant major depression, " Journal of Clinical Psychiatry, vol. 75, no. 5, pp. e417-e423, 2014.
19. D. A. Luckenbaugh, M. J. Niciu, D. F. Ionescu et al., "Do the dissociative side effects of ketamine mediate its antidepressant effects?" Journal of Affective Disorders, vol. 159, pp. 56-61, 2014.
20. N. Lundin, M. Niciu, D. Luckenbaugh et al., "Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine, " Pharmacopsychiatry, vol. 47, no. 4-5, pp. 141-144, 2014.
21. R. Vadnal and R. Parthasarathy, "Myo-inositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate, " Neuropsychopharmacology, vol. 12, no. 4, pp. 277-285, 1995.
22. H. K. Manji, R. Etcheberrigaray, G. Chen, and J. L. Olds, "Lithium decreases membrane-associated protein kinase C in hippocampus: Selectivity for the isozyme, " Journal of Neurochemistry, vol. 61, no. 6, pp. 2303-2310, 1993.
23. N. Kirshenboim, B. Plotkin, S. B. Shlomo, O. Kaidanovich-Beilin, and H. Eldar-Finkelman, "Lithium-mediated phosphorylation of glycogen synthase kinase-3 involves PI3 kinasedependent activation of protein kinase C-, " Journal ofMolecular Neuroscience, vol. 24, no. 2, pp. 237-245, 2004.
24. M. Shim and R. C. Smart, "Lithium stabilizes the CCAAT/ enhancer-binding protein a (C/EBP) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity, " The Journal of Biological Chemistry, vol. 278, no. 22, pp. 19674-19681, 2003.
25. S. M. Stahl, "Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels, " Journal of Clinical Psychiatry, vol. 65, no. 6, pp. 738-739, 2004.
26. H. M. Emrich, D. von Zerssen, W. Kissling, and H. J. Mller, "On a possible role of GABA in mania Therapeutic efficacy of sodium valproate, " Advances in Biochemical Psychopharmacology, vol. 26, pp. 287-296, 1981.
27. G. Chen, L.-D. Huang, Y.-M. Jiang, and H. K. Manji, "The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3, " Journal of Neurochemistry, vol. 72, no. 3, pp. 1327-1330, 1999.
28. C.-T. Chiu, Z. Wang, J. G. Hunsberger, and D.-M. Chuang, "Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder, " Pharmacological Reviews, vol. 65, no. 1, pp. 105-142, 2013.
29. Y. Leng, M. H. Liang, M. Ren, Z. Marinova, P. Leeds, and D.-M. Chuang, "Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: Roles of glycogen synthase kinase-3 inhibition, " The Journal of Neuroscience, vol. 28, no. 10, pp. 2576-2588, 2008.
30. J.A. Quiroz, N. A. Gray, T. Kato, and H.K. Manji, "Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder, " Neuropsychopharmacology, vol. 33, no. 11, pp. 2551-2565, 2008.
31. M. J. Kempton, J. R. Geddes, U. Ettinger, S. C. R. Williams, and P. M. Grasby, "Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder, " Archives of General Psychiatry, vol. 65, no. 9, pp. 1017-1032, 2008.
32. R. MacHado-Vieira, M. G. Soeiro-De-Souza, E. M. Richards, A. L. Teixeira, and C. A. Zarate Jr., "Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach, " World Journal of Biological Psychiatry, vol. 15, no. 2, pp. 84-95, 2014.
33. A. Villaseñor, A. Ramamoorthy, M. Silva dos Santos et al., "A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks, " British Journal of Pharmacology, vol. 171, no. 8, pp. 2230-2242, 2014.
34. N. Li, B. Lee, R.-J. Liu et al., "mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, " Science, vol. 329, no. 5994, pp. 959-964, 2010.
35. A. E. Autry, M. Adachi, E. Nosyreva et al., "NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses, " Nature, vol. 475, no. 7354, pp. 91-96, 2011.
36. A. B. M. Cunha, B.N. Frey, A.C. Andreazza et al., "Serumbrainderived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes, " Neuroscience Letters, vol. 398, no. 3, pp. 215-219, 2006.
37. J. F. Tramontina, A. C. Andreazza, M. Kauer-SantAnna et al., "Brain-derived neurotrophic factor serum levels before and after treatment for acute mania, " Neuroscience Letters, vol. 452, no. 2, pp. 111-113, 2009.
38. C. A. Zarate Jr., N. Brutsche, G. Laje et al., "Relationship of ketamines plasma metabolites with response, diagnosis, and side effects in major depression, " Biological Psychiatry, vol. 72, no. 4, pp. 331-338, 2012.
39. J. R. Calabrese, M.D. Shelton, C. L. Bowden et al., "Bipolar rapid cycling: focus on depression as its hallmark, " Journal of Clinical Psychiatry, vol. 62, supplement 14, pp. 34-41, 2001.
40. M. E. Thase, "Bipolar disorder maintenance treatment: monitoring effectiveness and safety, "The Journal of Clinical Psychiatry, vol. 73, no. 4, article e15, 2012.